P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment

P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 31; pp. S124 - S125
Main Authors: Ogasawara, S., Llovet, J., El-Khoueiry, A., Vogel, A., Madoff, D., Finn, R., Ren, Z., Modi, K., Li, J., Siegel, A., Dubrovsky, L., Kudo, M.
Format: Journal Article
Language:English
Published: 01-07-2020
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
DOI:10.1016/j.annonc.2020.04.189